BPC-157 + TB-500 - 10+10mg
New

BPC-157 + TB-500 - 10+10mg

€169.00

BPC-157 is a penta-decapeptide comprised of 15 amino acids. It has been shown to have effects on:

- Fast recovery from muscle tears

- Wound healing

- Ligament healing

- Healing and prevention of gastric ulcers and inflammatory bowel diseases

- Blood vessel growth

- The coagulation cascade

- Nitric oxide generation

- Immune system function

- Gene expression Hormone regulation


Thymosin Beta-4 is a 43 amino acid peptide sequence. Recent research and clinical trials done utilizing TB-500 (Thymosin Beta 4) have established that it has a variety of advantages, including the following:

- Improves blood vessel growth

- Controls wound healing

- Reduces inflammation

- Minimises oxidative injury to the heart and central nervous system

- Additionally, it aids in tissue regeneration, remodeling, and protection of wounded or damaged tissues.


Description

STRUCTURE

BPC-157 - 10mg

Sequence: Gly-Glu-Pro-Pro-Pro-Gly- Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Molecular Formula: C62H98N16O22

Molecular Weight: 1419.556 g/mol

CAS: 137525-51-0

Peptide Purity: greater than 99%

Other details: No TFA Salt

TB-500 - THYMOSIN BETA-4 (43AA)-10mg

Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser  

Molecular Formula: C212H350N56O78S

Molecular Weight: 4963.4408 g/mol

CAS number: 77591-33-4

Peptide purity: greater than 98%

Other details: No TFA Salt


Storage: Lyophilized peptide must be stored at -20°C and peptide solution at +4°C


DESCRIPTION

BPC-157

The natural function of BPC-157 in the gastrointestinal tract is to preserve the integrity of the mucosal barrier. This barrier protects the underlying tissues from the potentially damaging effects of gastric acid, bile, or other compounds that are required for digestion and the absorption of nutrients from food. BPC-157 is produced naturally in the GI tract. The recruitment of fibroblasts is necessary for the performance of at least a portion of this function. Because of the dose-dependent impact that BPC-157 has on the spread of fibroblasts in culture and in vivo, the cells are accelerated in their ability to both proliferate and migrate. Fibroblasts are essential to the process of wound healing since they are the cells that are responsible for the deposition of extracellular matrix proteins such as collagen, fibrin, elastin, and others.

BPC-157 is a powerful angiogenic factor that speeds up the rate of proliferation and growth of endothelial cells, which are the cells that line blood arteries. The pace at which collateral blood vessels form in response to ischemia is shown to be significantly accelerated by the peptide, according to research conducted on rats. Even though this effect has been seen most frequently in the gastrointestinal tract, there is evidence that it also benefits the cardiovascular system, the nervous system, and the muscles. This leads researchers to believe that BPC-157 could be used not only as a treatment for conditions such as stroke and heart attack but also as a probative peptide in research aimed at determining how to best promote healing after ischemic injury.

It should not come as a surprise that BPC-157 has demonstrated good results in animal models of the tendon, ligament, bone, as well as other connective tissue injuries. Given its functions in fibroblast recruitment and blood vessel formation, this discovery should not come as a surprise. Injuries to tendons and ligaments take a long time to heal in large part because these tissues do not get an adequate amount of blood flow. The pace at which fibroblasts and other cells that aid in wound healing can travel to the site of the damage is slowed down by an inadequate blood supply, which, as a result, reduces the total amount of repair that can take place. In the context of the tendon, ligament, and bone damage, research conducted in vitro as well as in vivo on rat tendons has shown that BPC-157 stimulates the formation of collateral connections and increases the density of fibroblasts. According to the findings of this study, the hormone BPC-157 promotes healing in these tissues at a rate that is superior to that achieved by bFGF, EFG, and VGF.

According to studies conducted on rats, BPC-157 can reduce the levels of oxidative stress indicators such as nitric oxide and malondialdehyde (MDA). Because of this, BPC-157 is a potent antioxidant. This quality of the peptide is reinforced even further by studies demonstrating that it may inhibit the generation of reactive oxygen species in the gastrointestinal system.

It has been discovered that BPC-157 may mitigate the negative effects of some medicines, including nonsteroidal anti-inflammatory drugs (NSAIDs), pharmaceuticals used to treat mental health disorders, and a variety of cardiac treatments.

Wound and Gut Healing

Endogenous BPC production in the stomach maintains the integrity of the entire GI tract, protecting the mucosal barrier from acids and exogenous substances and foods that are known to damage tissues. BPC-157 not only maintains the integrity of the gut, but also promotes systemic healing of wounds, not limited to burns, gastric ulcers, and lacerations by promoting angiogenesis, overall cell growth and repair.

Cell Growth and Angiogenesis

Research has shown that BPC-157 increases blood vessel growth in all areas of the body. A study of chicken embryos demonstrated that BPC-157 increases vascular growth through the activation of cell surface receptors in the Nitrous Oxide pathway, growing new vessels toward the injury. This implies potential treatment of heart disease, overall cellular repair for life extension, and other general healing.

Drug Side Effects, Ulcers and Heart Attacks

BPC-157 has been shown to heal gastrointestinal, liver and brain lesions as a result of side effects produced by the use of NSAIDS, or non-steroidal anti-inflammatory drugs such as Celecoxib, Ibuprofen, Advil, etc. NSAIDS are known to cause ulcers, internal bleeding, heart attacks and various other dangerous conditions.

Anti-Inflammatory and Antioxidant

A study demonstrated that BPC-157 is a powerful antioxidant by reducing free radical formation via the Nitric Oxide system, attenuating duodenal lesions in rats by significantly decreasing oxidative stress.

Brain-Gut Axis Benefits and Antidepressant

BPC-157 was shown to modulate serotonin and dopamine with central influence benefits. A comparison with antidepressants found that BPC-157 was effective in attenuating depression.



TB-500 - THYMOSIN BETA-4

A hormone produced by the thymus is called thymosin. Its main purpose is to promote the development of T cells, a significant immune system component. Additionally, thymosin aids in the conversion of B cells into plasma cells, which make antibodies.

One of the main mechanisms of action of Thymosin Beta-4 is its regulation of Actin.  The protection, regeneration, and remodeling of wounded or damaged tissues have been revealed to be significantly influenced by Tβ 4. Platelets and many other kinds of cells produce Tβ4 after an injury to preserve the most injured cells and tissues, as well as to lessen inflammation and microbial development.

Recent research has shown that a gene called Tβ4 is the first to get activated after damage. Tβ4 helps the body start the healing process by helping new blood vessels grow in the wounded region, bringing blood, nutrients, and healing agents to the area. Tβ4 has anti-inflammatory effects as well and acts to reduce the production of cytokines, which are inflammatory agents. Tβ4 may have a wide-ranging effect since inflammation is a major contributor to the symptoms of many other disorders (such as Lyme disease, CFS, FM, autoimmune diseases, infections, etc.).

Tβ4 has become a useful therapeutic agent as a result of the function it plays in the immune regulatory process. HIV, AIDS, influenza, colds, and other illnesses have all been treated using Tβ4. 

TB 500 may also go through the body over a great distance due to its distinct molecular structure. This allows it to have a "systemic" impact, locating and helping the bodily parts that are injured. Reduced inflammation and improved flexibility are two additional advantages of taking TB 500. There have even been some reports of regrowing and darkening of hair.

The use of Tβ4 in mammalian cells caused wound healing in cutaneous, corneal, and cardiac cells.

These claims are backed by research by Phlip and Kleinman, who used Tβ4 as a topical therapy to repair lesions caused by heptanol and alkali to the skin and eyes of rats and mice.

The mice were treated twice daily with liquid ocular drops of 5 micrograms/5 microliters. The corneal epithelium quickly traveled across the cornea's surface when the drops were applied to heal the tissue that had been destroyed by the alkali insult. Because the alkali damage is seen as a burn, there is a significant degree of inflammation there. Topical Tβ4 drops reduce inflammation by increasing nF kappa b, activating nF kappa b, and inhibiting the production of TNF cytokine and matrix metalloproteinases. Tβ4 also boosts the production of laminin-5, which helps in maintaining cellular contact or migration in the corneal epithelium as well as lowering levels of apoptosis and boosting angiogenesis in tests.

The effects of Tβ4 on the skin's natural healing process were also investigated by the researchers. Tβ4 hydrogel or PBS was applied to full-thickness punch dermal wounds on rats and mice, with dosages ranging from 5 to 50 micrograms/50 microliters/wound. The use of Tβ4 increased the rate of collagen deposition, keratinocyte migration, and angiogenesis in cutaneous wound healing. Different branches of this same research, which used rats and mice, found that using Tβ4 sped up the healing process in the test animals. These test subjects had various types of impaired healing, such as diabetes or old age.

Tβ4 has been proven to have favorable benefits in numerous animals when treating cardiovascular illness, nerve damage, septic shock, and cutaneous injuries. Tβ4 was typically injected intracardially at a dosage of 400 ng; retro-infusion doses were typically in the range of 15 mg.

Tβ4 is regarded as "cardioprotective"; it was shown in mouse models of coronary ligation that Tβ4 encouraged healing across the heart muscle. Additionally, it was shown to inhibit circulatory system damage in the sheep refusion injury model. Tβ4 improves the function of the heart, lowers levels of fibrosis, and increases cell survival rates by activating integrin-linked kinase and boosting cell migration, survival, and activation in the heart.

As was previously mentioned, Tβ4 aids in reducing cytokine levels that cause inflammation in the body. Phlip and Kleinman administered an endotoxin to rats to test the anti-inflammatory effects of Tβ4 since proinflammatory cytokines contribute to septic shock. Following the injection of the endotoxin, Tβ4 was given right away, two hours later, and then again four hours later.

The lethality of endotoxin-induced septic shock and the inflammatory mediators associated with it were both shown to be significantly decreased after the T-4 dose. The fascinating phenomenon seen by the researchers was that Tβ4 levels spontaneously decreased in rats when sepsis was induced. Tβ4 may be an essential treatment for sepsis as shown by the fact that its levels were reduced in both rats with endotoxin injection and those with non-induced septic shock.

Similar to the cardiovascular system, both in vivo and in vitro, Tβ4 is regarded as protective in the neurological system. Kainic acid was administered to rats to cause the loss of hippocampus neurons. Tβ4 was given to the rats twice daily for five days after the kainic acid treatment to stop the loss of neurons.

In addition, animals with autoimmune encephalomyelitis received 6 mg/kg of Tβ4 every three days after the illness was first caused. Treatment with Tβ4 has been proven to help lower overall inflammation, increase the number of mature oligodendrocytes, and aid enhance functioning. Tβ4 has also been shown to be protective in vitro against ethanol toxicity and glutamate-induced toxicity.

TB-500 was shown to be a gene that was four to six-fold up-regulated during the early stages of blood vessel development and was shown to encourage the development of new blood cells from the existing capillaries. When given subcutaneously, this peptide, which is found in wound fluid, improves wound healing, and muscle growth, and quickens the recovery of muscle fibers and their cells. The fact that TB-500 encourages cell migration by specifically interacting with actin in the cell cytoskeleton is another crucial aspect of the compound. A core tiny amino acid long-actin binding domain has been shown to possess properties for both blood cell proliferation and wound healing. Accelerating the migration of keratinocytes and endothelial cells reveals these properties. Additionally, it boosts the production of enzymes that break down the extracellular matrix.

Thymosin Beta 4 (TB-500), which has been the subject of recent investigations and clinical trials, has been shown to have several positive effects on various body parts:

● Differentiation of blood vessel endothelial cells

● In dermal tissues, angiogenesis (the formation of new blood cells from pre-existing capillaries)

● Keratinocyte migration

● Collagen deposition

● Reduces tissue inflammation in joints

● Increased strength and endurance, along with significant improvements in muscle mass

● Stretching connective tissue improves flexibility.

● Prevents the development of fibrous bands and adhesions in the muscles, tendons, and ligaments.

● Reduces muscular cramps

● Greater muscular tone

● Increased cellular substance exchange

● Increases tissue regeneration

● Decreases the extent of the infarct and enhances cardiac function

● Therapeutic impact on the dry eye condition and corneal injuries

● Hepatic antifibrotic action

● Speeds up hair growth



REFERENCES

A. Goldstein et al., "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications" [PubMed]

A. Goldstein et al., "Advances in the basic and clinical applications of thymosin β4" [PubMed]

D. Crockford et al., "Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications" [PubMed]

G. Sosne et al., "Biological activities of thymosin beta4 defined by active sites in short peptide sequences" [PubMed]

E.G. Yarmola et al., "Thymosin beta4: actin regulation and more" [PubMed]

M. Badamchian et al., "Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock" [PubMed]

A. Gonzales-Franquesa et al., "Discovery of thymosin β4 as a human exerkine and growth factor" [PubMed]

J.D. Young et al., "Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids" [PubMed]

M.R. Bubb "Thymosin beta 4 interactions" [PubMed]

Y. Xing et al., "Progress on the Function and Application of Thymosin β4" [PubMed]

N. Shomali et al., "A new insight into thymosin β4, a promising therapeutic approach for neurodegenerative disorders" [PubMed]

S. Munshaw et al., "Thymosin β4 protects against aortic aneurysm via endocytic regulation of growth factor signaling" [PubMed]

G. Renga et al., "Thymosin β4 limits inflammation through autophagy" [PubMed]

Y. Wang et al., "Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in Pseudomonas aeruginosa-Induced Keratitis" [PubMed]

K.W. Freeman et al., "Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling" [PubMed]

G. Sosne et al., "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury" [PubMed]

J. Zhang et al., "Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system" [PubMed]

Rui Yu et al., "Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection" [PubMed]

M. Hsieh et al., "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation" [PubMed]

J. Vukojevic et al.,  "Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157" [PubMed]

N. Jelovac et al., "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats" [PubMed]

D. Strinic et al., "BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats" [PubMed]

K. Skrlec et al., "Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities" [PubMed]

C. Chang et al., "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration" [PubMed]

S. Seiwerth et al., "BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing" [PubMed]

P. Sikiric et al., "Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing" [PubMed]



DISCLAIMER

This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.

Data sheet

bptb1010

Customers who bought this product also bought: